Friday, Spectral Molecular Imaging (SMI), a wholly-owned subsidiary of Cascade Technologies, Inc., announced the availability of a new Investor Information Brief outlining the company’s proprietary technology and its strategy to develop a line of optical imaging devices for earlier detection of cancer and other major disease.
The subsidiary is applying proprietary high-resolution optical imaging technology to develop an assortment of imaging devices designed for the purpose of detecting major disease and assessing the health of tissues during and after surgery. The technology was originally developed for use in satellite reconnaissance.
The Company’s hyperspectral imaging technology is designed to enable the live, real-time identification and analysis of molecular, cellular and tissue features indicating cancer and other serious conditions, significantly earlier and more accurately than currently possible. MelaSpect(tm), also among the company’s products in development, is an imaging device designed to provide early and reliable detection of skin cancer, including melanoma, the deadliest type of skin cancer.
Skin cancer is the most common type of cancer in the U.S., with estimates pointing to more than one million Americans diagnosed every year. Melanoma, the fastest growing cancer worldwide, is responsible for approximately 75% of all deaths from skin cancer. Early detection is currently the only effective means of fighting the skin disease, but at present dermatologists rely principally on visual examinations of patients to identify suspicious skin tissues, an approach that can lead to ambiguous and inaccurate diagnosis.
SMI is also applying its spectral imaging technology to develop products to monitor tissue health during both minimally invasive and major procedures, including open-heart surgery.
“SMI’s proprietary technology addresses medical needs that are not only vitally important today, but will become more significant within the next decade,” stated Daniel L. Farkas, Ph.D., Chairman of SMI. “Our goal is for MelaSpect(tm) and our other devices to become part of the standard of care in cancer detection, significantly improving patient outcomes while lowering healthcare costs.”